- Details
- Description
Packaging Size:
56c/bottles
Strength:
3mg
Composition:
Tunlametinib
Treatment:
Advanced melanoma harboring NRAS mutations
Form:
capsule
Brand:
科露平
Quantity Unit:
3mg*56c/Box
Manufacturer:
Shanghai KeChow Pharma, Inc.,China
Tunlametinib (HL-085) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor, for the treatment of solid tumours with RAS and RAF mutations, including melanoma, non-small cell cancer (NSCLC), colorectal cancer (CRC) and neurofibromatosis type 1 (NF1) plexiform neurofibromas.
- Tunlametinib sold under the brand name 科露平® in china.
March 18, 2024, China’s National Medical Products Administration (NMPA) has approved tunlametinib (HL-085) for the treatment of patients with advanced melanoma harboring NRAS mutations who were previously treated with anti–PD-1/PD-L1 therapy.
